尼妥珠单抗联合伊匹单抗与单用尼妥珠单抗治疗晚期黑色素瘤患者的疗效和安全性:系统综述和荟萃分析。

IF 2.9 3区 医学 Q2 ONCOLOGY Expert Review of Anticancer Therapy Pub Date : 2024-05-01 Epub Date: 2024-03-29 DOI:10.1080/14737140.2024.2336106
Shuting Cui, Xiaozhe Sun, Junxi Gao
{"title":"尼妥珠单抗联合伊匹单抗与单用尼妥珠单抗治疗晚期黑色素瘤患者的疗效和安全性:系统综述和荟萃分析。","authors":"Shuting Cui, Xiaozhe Sun, Junxi Gao","doi":"10.1080/14737140.2024.2336106","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Annual melanoma incidence in the US is escalating.</p><p><strong>Objective: </strong>Comprehensive evaluation of nivolumab alone or with ipilimumab for advanced melanoma treatment.</p><p><strong>Research design and methods: </strong>A systematic search was conducted across PubMed, Embase, Web of Science, and Cochrane databases, extending until August 2023. A range of outcomes were evaluated, encompassing overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), disease-free survival (DFS), adverse events (both any and serious), complete response rate, mortality rate, and recurrence rate in patients with advanced melanoma.</p><p><strong>Results: </strong>This analysis was conducted on seven relevant studies, involving 2,885 patients. The baseline characteristics of both groups were found to be comparable across all outcomes, with the exception of tumor size. The pooled analysis did not reveal any significant disparities, except for PFS, where the nivolumab-ipilimumab treatment group demonstrated a significantly longer PFS compared to the nivolumab group. However, there was a notable discrepancy in any adverse events (Odds Ratio (OR): 2.69; 95% Confidence Interval (CI): 1.96, 3.69; <i>p</i> < 0.00001) and serious adverse events (OR: 3.59; 95% CI: 2.88, 4.49, <i>p</i> < 0.00001) between the two groups, suggesting that the safety profile of nivolumab combined with ipilimumab was inferior.</p><p><strong>Conclusions: </strong>Given diversity and potential biases, oncologists should base immunotherapy decisions on professional expertise and patient characteristics.</p><p><strong>Registration: </strong>PROSPERO registration number: CRD42023453484.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"283-291"},"PeriodicalIF":2.9000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis.\",\"authors\":\"Shuting Cui, Xiaozhe Sun, Junxi Gao\",\"doi\":\"10.1080/14737140.2024.2336106\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Annual melanoma incidence in the US is escalating.</p><p><strong>Objective: </strong>Comprehensive evaluation of nivolumab alone or with ipilimumab for advanced melanoma treatment.</p><p><strong>Research design and methods: </strong>A systematic search was conducted across PubMed, Embase, Web of Science, and Cochrane databases, extending until August 2023. A range of outcomes were evaluated, encompassing overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), disease-free survival (DFS), adverse events (both any and serious), complete response rate, mortality rate, and recurrence rate in patients with advanced melanoma.</p><p><strong>Results: </strong>This analysis was conducted on seven relevant studies, involving 2,885 patients. The baseline characteristics of both groups were found to be comparable across all outcomes, with the exception of tumor size. The pooled analysis did not reveal any significant disparities, except for PFS, where the nivolumab-ipilimumab treatment group demonstrated a significantly longer PFS compared to the nivolumab group. However, there was a notable discrepancy in any adverse events (Odds Ratio (OR): 2.69; 95% Confidence Interval (CI): 1.96, 3.69; <i>p</i> < 0.00001) and serious adverse events (OR: 3.59; 95% CI: 2.88, 4.49, <i>p</i> < 0.00001) between the two groups, suggesting that the safety profile of nivolumab combined with ipilimumab was inferior.</p><p><strong>Conclusions: </strong>Given diversity and potential biases, oncologists should base immunotherapy decisions on professional expertise and patient characteristics.</p><p><strong>Registration: </strong>PROSPERO registration number: CRD42023453484.</p>\",\"PeriodicalId\":12099,\"journal\":{\"name\":\"Expert Review of Anticancer Therapy\",\"volume\":\" \",\"pages\":\"283-291\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Review of Anticancer Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14737140.2024.2336106\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/29 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2336106","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:美国每年的黑色素瘤发病率不断攀升:美国每年的黑色素瘤发病率不断攀升:研究设计与方法:在PubMed、Embase、Web of Science和Cochrane数据库中进行了系统检索,检索期至2023年8月。对一系列结果进行了评估,包括晚期黑色素瘤患者的总生存期(OS)、无复发生存期(RFS)、无进展生存期(PFS)、无疾病生存期(DFS)、不良事件(包括任何不良事件和严重不良事件)、完全应答率、死亡率和复发率:这项分析针对七项相关研究进行,涉及 2,885 名患者。除肿瘤大小外,两组患者的基线特征在所有结果中均具有可比性。汇总分析未发现任何显著差异,但PFS除外,与nivolumab组相比,nivolumab-ipilimumab治疗组的PFS明显更长。然而,在任何不良事件方面都存在明显差异(比值比(OR):2.69;95% 置信区间(CI):1.96, 3.69;P结论):考虑到多样性和潜在的偏见,肿瘤学家应根据专业知识和患者特征做出免疫疗法决定:PROSPERO 注册号:CRD42023453484CRD42023453484。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis.

Background: Annual melanoma incidence in the US is escalating.

Objective: Comprehensive evaluation of nivolumab alone or with ipilimumab for advanced melanoma treatment.

Research design and methods: A systematic search was conducted across PubMed, Embase, Web of Science, and Cochrane databases, extending until August 2023. A range of outcomes were evaluated, encompassing overall survival (OS), recurrence-free survival (RFS), progression-free survival (PFS), disease-free survival (DFS), adverse events (both any and serious), complete response rate, mortality rate, and recurrence rate in patients with advanced melanoma.

Results: This analysis was conducted on seven relevant studies, involving 2,885 patients. The baseline characteristics of both groups were found to be comparable across all outcomes, with the exception of tumor size. The pooled analysis did not reveal any significant disparities, except for PFS, where the nivolumab-ipilimumab treatment group demonstrated a significantly longer PFS compared to the nivolumab group. However, there was a notable discrepancy in any adverse events (Odds Ratio (OR): 2.69; 95% Confidence Interval (CI): 1.96, 3.69; p < 0.00001) and serious adverse events (OR: 3.59; 95% CI: 2.88, 4.49, p < 0.00001) between the two groups, suggesting that the safety profile of nivolumab combined with ipilimumab was inferior.

Conclusions: Given diversity and potential biases, oncologists should base immunotherapy decisions on professional expertise and patient characteristics.

Registration: PROSPERO registration number: CRD42023453484.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.10
自引率
3.00%
发文量
100
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
期刊最新文献
Unlocking survival benefits: primary tumor resection in de novo stage IV breast cancer patients. Statin use and ovarian cancer outcomes. Development of a nomogram for predicting postoperative recurrence of cervical intraepithelial neoplasia using immunohistochemical and clinical parameters. Impact of the 21-gene recurrence score testing on chemotherapy selection and clinical outcomes in T3N0 luminal breast cancer. The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1